News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Arboviruses are spreading beyond tropical and subtropical regions due to climate change, population growth, and increased ...
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food and Drug ...
On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results